Cromos™ Pharma helps Regen Biopharma in filing of an Investigational New Drug (IND) application with the FDA

Regen BioPharma announced today filing of an Investigational New Drug (IND) application with the FDA to initiate clinical trials assessing the company’s HemaXellerate I™ stem cell drug in patients with drug-refractory aplastic anemia. Cromos Pharma’s team took active part in IND application preparation.

More details can be found at Regen Biopharma website and press-release.